0000950170-24-032432.txt : 20240315
0000950170-24-032432.hdr.sgml : 20240315
20240315200527
ACCESSION NUMBER: 0000950170-24-032432
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240314
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JEFFS ROGER
CENTRAL INDEX KEY: 0001231615
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37635
FILM NUMBER: 24756605
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axsome Therapeutics, Inc.
CENTRAL INDEX KEY: 0001579428
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 454241907
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10007
BUSINESS PHONE: (212) 332-3241
MAIL ADDRESS:
STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10007
4
1
ownership.xml
4
X0508
4
2024-03-14
0001579428
Axsome Therapeutics, Inc.
AXSM
0001231615
JEFFS ROGER
C/O AXSOME THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, 22ND FLOOR
NEW YORK
NY
10007
true
false
false
false
true
Common Stock
2024-03-14
4
M
false
13000
22.03
A
133756
D
Common Stock
2024-03-14
4
S
false
13000
69.702
D
120756
D
Common Stock
2024-03-14
4
M
false
16976
25.53
A
137732
D
Common Stock
2024-03-14
4
S
false
16976
69.702
D
120756
D
Common Stock
2024-03-15
4
M
false
2347
29.91
A
123103
D
Common Stock
2024-03-15
4
S
false
2347
71.6072
D
120756
D
Common Stock
46912
I
GRAT
Stock Option (Right to Buy)
22.03
2024-03-14
4
M
false
13000
0.00
D
2020-06-07
2029-06-07
Common Stock
13000
0
D
Stock Option (Right to Buy)
25.53
2024-03-14
4
M
false
16976
0.00
D
2023-06-03
2032-06-03
Common Stock
16976
0
D
Stock Option (Right to Buy)
29.91
2024-03-15
4
M
false
2347
0.00
D
2022-03-04
2032-03-04
Common Stock
2347
0
D
Represents an exercise of stock options.
Such transaction was pursuant to a pre-approved 10b5-1 plan.
Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
Represents additional shares held indirectly by the Reporting Person prior to March 14, 2023.
/s/ Herriot Tabuteau, M.D., Attorney-in-Fact
2024-03-15